Back to results
US 10,094,836 B2Granted
SLCO1B3 genotype
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsWilliam D. Figg, Alex Sparreboom, Akinobu Hamada, Douglas K. Price, Tristan M. Sissung
Life of this patent
Estimating the term…
Abstract
The invention relates methods of identifying and predicting inter-patient differences in prognostic prediction for survival in androgen independent prostate cancer. It further related to methods for determining and exploiting such differences to improve medical outcomes. Moreover, it provides methods for determining if a subject has prostate cancer.
Claims3
A method of treating a subject having prostate cancer comprising
- determining a SLCO1B3 genotype status of a subject having prostate cancer, wherein a homozygous 334GG and/or 699AA SLCO1B3 genotype is indicative of a subject that will respond to androgen-deprivation therapy, and wild-type SLCO1B3 genotype is indicative of a patient that is unresponsive to androgen-deprivation therapy;
- and
- treating the subject having wild-type SLCO1B3 genotype by discontinuing androgen-deprivation therapy and administering a therapeutically effective amount of an anti-neoplastic agent to the subject, thereby improving survival of the subject having wild-type SLCO1B3 genotype.
Dependencies are inferred from the claim text.